过去一周是加密历史上的一个黑暗时期，该行业的总市值自2021年7月以来首次降至1.2万亿美元。 这场动荡在很大程度上是由于实时解体造成的 $Terra(LUNA.CC)$.
上周，由于区块链的原生代币跌至0.0003美元的低点，接近零，Terra已正式停止区块生产。
在暴跌的起步中...

2022年1月3日，星期一
作者：吉米
$Nu Holdings(NU.US)$ $PayPal(PYPL.US)$ $Sea(SE.US)$ $联合大陆航空(UAL.US)$

Q&A is a session under a company's earnings conference that institutional and retail investors ask some most-concerned questions to the management. On this page, you may discover info that might affect the stock price in the following weeks. $Moderna(MRNA.US)$
Key Takeaways:
Attitudes: some Q4 deliveries may still move to early 2022. In 2022 there might be a large volume, but way lower than what the commercial market could drive.
Goals: expect to deliver 700 to 800 million doses in 2021. This compares to the prior outlook of 800 million to 1 billion doses.
For 2022, can you walk through the supply aspects. Are you still guiding to up to 3 billion doses here?
Yes, we could see make up to 3 billion doses in terms of material. As you know, that number was really depending on the booster dose. And now that we're on the other side of that decision with the 50-microgram dose, we confirmed we could make up to 3 billion doses, if there was a need for it. The challenge in 2022 is going to really be around product form because as the market moves to an endemic market, you're going to need basically vials to be able to go to less number of dose per vile.
You lowered 2021 a little bit, I think, by 5 billion, but raised 2022, 2022 by 5 billion. Is that a timing shift of deliveries? And how much of that is just option contracts as you think about 2022?
On '21, so there's two things I think that is driving, first is, of course the lower volume. And the second one is price. As you know, we are working very hard with several governments to send products that they have bought for high-income countries like the U.S. to low-income country this side of Christmas. When we announced our African Union partnership, the U.S. decided to delay to Q2, the delivery over December quarter. That volume is going to African Union at a low tier price. And some orders that are moving from December to January on the supply volume side of things.
Given your comments on the call about potentially moving into the endemic phase by the second half of next year. Should we think about 2022 revenue as being weighted toward the first half of the year?
On the endemic and the ventilation of the sales over the year, I think it will be dangerous to assume at this stage one way or other in terms of first half and second half because of volume and also pricing. As you get a sense, the COVAX, the African Union and some BARDA deals we have are lower prices. And so there might be a large volume, but probably way lower than what the commercial market could drive, which we believe is going to be above what has been the pandemic price again because of volume. I would be cautioned that assuming Q1 to be lower and Q2 is a bit too early.
Just curious on the guidance for the 2 billion guidance for the U.S. fall 2022 booster market. Can you help us understand what assumptions are sort of built into that number?
So on the fall of '22, so the commercial team has spent quite a lot of time modeling different assumptions in terms of volume of people who want the boost, market share, and, of course, pricing. I cannot comment further for competitive reason right now, especially on the pricing piece, but we will do that in due time. But indeed it's typical commercial analysis that the team that has done many times before in other companies have run through the last few months.
How much perspective can you give us on you're able to potentially compete for share on contracting in EU, the competitor Pfizer/BioNTech locked in pretty large contracts on volume for the next two years?
The other vaccines that other than mRNA, I'm not sure, used anymore as my understanding, they're mostly given through COVAX. I think we have an interesting opportunity because as I shared you talk to healthcare leaders, health minister, as you get more and more data that Paul shared, we have a better and better understanding that the two mRNA vaccines are not the same. And so again, as we look into 2022, we already have a contract with Europe in '22. And we are discussing also with country by country on the data and using the benefit of the Moderna vaccine versus the other one.
This article is a script from the Q&A session of MRNA earnings call on Nov 2. In order to facilitate reading, we have made appropriate cuts. If you want to know more details, you can click here for details.

来自不同平台的排名前五的股票是来自主要投资平台和社交媒体的热门股票的集合，为投资者提供了各地的热门股票清单。
Moomoo 从Robinhood和Investing.com中选择了最热门的股票；从雅虎财经、Stocktwits和moomoomoo 中选择了最活跃的股票。
- $英伟达(NVDA.US)$ 今年股价飙升接近120％，创下历史新高。英伟达公司周四上涨至历史新高，创下历史新高，今年股价飙升至120％。这是该公司延长2021年涨幅的最新例子，该股已翻了一番多。
阅读更多：英伟达创下历史新高，今年股价飙升接近120％.
- $优步(UBER.US)$ 盘后股价最初下跌超过2％，此前在常规交易日下跌了约1％，收于45.27美元，但截至下午5点30分略有上涨。最佳。该公司表示，其总预订量同比增长57％，达到231亿美元，低于分析师预期的233亿美元。旅行也同比增长，同比增长39％，达到16.4亿次，低于分析师预期的16.9亿人次。受冠状病毒疫情影响的司机供应同比增长60％。
阅读更多：优步在叫车和送货方面的收入有所增加，但亏损也有所增加。
- $AMC院线(AMC.US)$ 正在进入包装食品市场，并将于明年开始在美国的购物中心售货亭、超市和便利店出售其爆米花。这家电影院公司计划在2022年上半年在购物中心推出多达五家AMC Theatres Popectry Popcorn门店、柜台和售货亭，并计划在2023年之前开设15家零售店。AMC首席执行官亚当·阿伦称此举对该公司来说是 “自然而合乎逻辑的”，在冠状病毒疫情之后，该公司一直在寻求实现收入多元化。
阅读更多：AMC将于2022年在购物中心售货亭、超市出售自有品牌的爆米花。

你好Mooer们，你在关注本周的收益吗？我们的挑战按图表划分的股票回来了！立即查看并加入赢取奖励:
挑战：看下面的图表，说出相应股票的名称。（即特斯拉、苹果、AMC）
规则：第一还有最后的在这篇文章的有效期内给出正确答案的摩尔将获胜！
奖励：两位幸运的获胜者将获得以下奖励 800 点积分每个！
有效期：请在之前的评论中留下您的答案2021 年 11 月 8 日美国东部时间上午 11:59/ 2021 年 11 月 9 日上午 12:59（新加坡标准时间）.
立即评论赢取！
小贴士：收益如何影响股价？
图表 1：
关键词-Covid 疫苗
图表 2：
关键词-销售预测下调
图表 3：
关键词-叫车

$贝莱德(BLK.US)$ rock n roll

哇